$23.430
-1.321 (-5.64%)Zum Schluss
BCAX-News
BCAX-Events
Bicara Therapeutics CEO Transition, Ryan Takes Over
"This transition marks a natural evolution for Bicara as we maintain strong enrollment momentum that enables a clear line of sight to a topline interim analysis which we believe will lead to an accelerated approval and subsequent launch of ficerafusp alfa in head and neck cancer. I am incredibly proud of what our team has accomplished so far-transforming bold science into meaningful impact for patients while establishing a strong foundation for future growth. Having worked closely with Ryan since Bicara's earliest days, I have seen firsthand his ability to translate strategy into disciplined execution, and we have been true partners in shaping the Bicara of today. I have complete confidence that he is the right leader to guide our next chapter," said Claire Mazumdar, Chief Executive Officer of Bicara Therapeutics. "In addition, I want to thank Ivan for serving as an early executive at Bicara, for leading us through private and public offerings during his tenure, and for establishing the early infrastructure for the Finance organization. In my new role, I look forward to continuing to help shape the future of Bicara-both on the Board and supporting the leadership team as they build on this momentum and continue creating lasting value for patients, employees, and shareholders."
Bicara Therapeutics Announces Leadership Transitions
Bicara Therapeutics announced strategic leadership transitions. Ryan Cohlhepp, Bicara's president and COO will succeed Claire Mazumdar as CEO effective January 1, 2027. As part of this planned evolution in leadership, Mazumdar will serve as vice chair of the board of directors and strategic advisor. Tanya Green, chief development officer, will succeed Cohlhepp as COO, effective January 1, 2027. Since joining Bicara in October 2025, Green has demonstrated enterprise-wide responsibility for driving operational strategy, execution, and organizational performance across key development and operational functions including global clinical operations, technical operations, regulatory affairs, quality, and program management. Jenn Larson has been appointed CFO and will succeed Ivan Hyep, effective August 12. Jenna Cohen will be promoted from chief corporate affairs officer to chief business officer, effective January 1, 2027. Greg Shiferman has been appointed chief legal officer effective August 31.
Bicara Therapeutics Advances ficerafusp alfa for HPV-Negative Head and Neck Cancer
"The first quarter of 2026 reflects strong progress as we work to position ficerafusp alfa as the cornerstone of treatment in HPV-negative head and neck cancer. In addition to advancing our FORTIFI-HN01 pivotal trial, we continued to enroll patients in additional Phase 1b signal-seeking studies as we aim to unlock the full blockbuster potential of ficerafusp alfa. Based on recent FDA discussions, we plan to initiate a randomized study to evaluate a loading and every-three-week maintenance dosing regimen - further differentiating ficerafusp alfa and expanding optionality for patients and providers. We also look forward to sharing an important data update at ASCO 2026, which will further characterize the role of TGF-beta in driving depth and durability of response across three 1L R/M HNSCC expansion cohorts," said Claire Mazumdar, Chief Executive Officer at Bicara Therapeutics. "Alongside our clinical progress, we are rapidly evolving toward becoming a commercial-stage company, and to support that evolution, today we announced several executive changes. David Raben has transitioned from Chief Medical Officer to a Senior Executive Advisor role after three years of instrumental contributions, and Bill Schelman, formerly Executive Vice President of Clinical Development, has stepped into the Chief Medical Officer role. We have also welcomed Chris Sarchi as our Chief Commercial Officer, who brings extensive oncology commercialization and leadership experience as we build toward launch."
Stock Futures Modestly Higher as Oil Prices Surge Above $100
Stock futures are modestly higher to start the week, indicating a potential rebound at the open following five consecutive weeks of declines across major indexes. Markets are stabilizing slightly after last week's sustained selloff, but the broader tone remains cautious as energy prices and geopolitical risk continue to dominate.The primary driver remains oil. Crude prices have surged back above $100 and, in some cases, are pushing toward the $110-$120 range as the Middle East conflict expands and supply concerns intensify. Disruptions tied to the Strait of Hormuz and the widening scope of the conflict, including additional regional involvement, are reinforcing expectations of prolonged tight supply.This is feeding into inflation expectations and interest rate outlooks. Markets are increasingly pricing out the likelihood of Federal Reserve rate cuts this year, as higher energy prices complicate the inflation trajectory. The result is continued pressure on equity valuations, particularly in rate-sensitive sectors.Global markets were mixed overnight, with sharp declines in parts of Asia but more stable trading in Europe and U.S. futures. This indicates that investors are beginning to adjust to elevated oil prices rather than reacting to each incremental move.Energy-related stocks are benefiting from higher crude prices, while broader equity markets continue to face headwinds from rising yields and slower growth expectations. Safe-haven demand is also re-emerging at the margins, with some support for assets like gold and the U.S. dollar.In pre-market trading, S&P 500 futures rose 0.79%, Nasdaq futures rose 0.78% and Dow futures rose 0.77%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -iQiyiup 10% after announcing a listing application form submission to the Hong Kong Stock Exchange for Class A ordinary sharesExpediaup 3% after Jefferies upgraded the stock to Buy from Hold with a price target of $300, up from $240CrowdStrikeup 3% after Wolfe Research upgraded shares to Outperform from Peer Perform with a $450 price targetSpireup 1% after entering into an agreement to sell its gas marketing business, Spire Marketing, to Boardwalk Pipelines for $215M in cashUP AFTER EARNINGS -Bicara Therapeuticsup 7%USA Rare Earthup 1%LOWER -Viridian Therapeuticsdown 38% after reporting data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye diseaseSyscodown 6% after announcing it will acquire Jetro Restaurant Depot for total enterprise value of $29.1B
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.